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tients and 62 peritoneal-dialysis patients at Siriraj hospital. Utility scores and the
correlation coefficientwith KDQOL-36were calculated. Percentages of respondents
with the ceiling and floor effects were compared for each of the different measure-
ment tools. RESULTS: Patient samples had a mean age of 60.2014.84 years. Mean
duration of dialysis were 7.445.42 years for hemodialysis patients, and 1.821.22
years for peritoneal-dialysis patients. The mean SF-6D score (0.7830.164) was
significantly higher than EQ-5D (UK: 0.7520.309, Thai: 0.6910.314), and VAS
(0.6660.196) scores. Most of the kidney specific dimensions were better correlated
with SF-6D than EQ-5D (UK and Thai preference weight) and VAS scores. Ceiling
effects were observed in the EQ-5D concerning both UK and Thai preference
weight, due to the fact that the EQ-5D differentiates less in the better health states,
whereas the floor effects were not clearly observed in any instrument tools.
CONCLUSIONS: SF-6D presented better correlation with kidney specific scales
while the responsiveness of EQ-5D utility scores was poor. One explanation might
be a ‘‘ceiling effect’’ of the EQ-5D. These findings implied that SF-6D utility scores
could reflect HRQoL status of dialysis patients better than EQ-5D and VAS.
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OBJECTIVES: To evaluate bootstrap techniques in comparing the validity of PRO
measures in discriminating among CKD patients and responding to longitudinal
changes.METHODS: The Kidney Disease Impact Scale (KDIS), CKD-specific legacy
(KDQOL Burden, Symptom, and Effect) and generic health (SF-12) scales were ad-
ministrated to 453 patients and re-administered to 110 patients after threemonths.
ANOVA-based relative validity (RV) coefficients were used to compare how well
each scale discriminated between three clinically-defined groups ordered in terms
of severity (Dialysis Stage 3-5 Transplant), and how responsive each scale was
to changes over time for self-evaluated Better, Same and Worse groups. Bootstrap
was used to construct confidence intervals (CIs) to determine whether the differ-
ences in RVs were significant in comparisons between each scale and the best
legacy measure - KDQOL Burden. Sample size, number of bootstrap iterations, and
type of CIs were varied to evaluate their impacts on CI using real and artificial data.
RESULTS: The sample size played a substantial role. 300 people for 3 groups were
suggested as theminimumnumber tomakemeaningful comparisons betweenRVs
using CI. Number of bootstrap replications (100 to 10,000) did not show an obvious
effect on bootstrap standard error, although 300 showed improvement over 100 on
CI. The bias-corrected and accelerated (BCa) type of CI was preferred for correcting
both bias and skewness in bootstrap distribution and for producing narrower CIs.
Using 95% CI and 300 sample size, differences in RVs were non-significant in com-
parisonswith KDQOL-Burden (RV1) for the following scales: SF-12 PCS (RV.6), PF
(RV.7), RP (RV .77), KDQOL-Effect (RV.99), and KDIS (RV1.13). CONCLUSIONS:
Bootstrapping appears to be valuable in testing the significance of differences in
the relative validity of these PRO measures from a statistical perspective. Samples
of 100 per group compared and 300 bootstrap replications are recommended.
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OBJECTIVES: The Consolidated Standards of Reporting Trials (CONSORT) state-
mentwas published in 2001 and updated in 2010, strongly recommended the use of
CONSORT diagram to report the flow of participants through each stages of the
trial. This studywas conducted to describe the level of compliance of the published
clinical trial in following the CONSORT recommendations and to estimate preva-
lence of the compliance.METHODS: A systematic literature search of all random-
ized controlled trials of anti-infectious agents published in the top 10 general med-
icine journals and top 5 infectious disease journals published in 2010. The journals
include: The New England Journal of Medicine, Journal of the American Medical
Association, British Medical Journal (Clinical Research Ed), Archives of Internal
Medicine, PloS Medicine, Annals of Internal Medicine, Clinical Infectious Diseases,
the Journal of Infectious Diseases, the Lancet Infectious Diseases, AIDS, Emerging
Infectious Diseases Journal, Annual Review of Medicine, Canadian Medical Associ-
ation Journal, and Annals of Medicine Journal. Each article was reviewed by two
independent investigators based on the reporting criteria recommended by the
CONSORT statement. Exclusion criteria included non-randomized control studies,
and studies not including intervention or control group. RESULTS: The study iden-
tified 129 published articles using explicit criteria on Medline search. A total of 73
randomized controlled trials met the inclusion criteria. Of 73 studies, 55 (75.34%)
articles included the CONSORT diagram. A comprehensive depiction of the CON-
SORT guidelines will be made and detail descriptions on the compliances will be
presented by journal types during the presentation. CONCLUSIONS: Randomized
controlled trials published in the top 10 general medicine journals and the top 5
infectious diseases journals in 2010 contain significant deficiencies in reporting the
CONSORT flow chart. The clarity and the completeness of a study could be im-
proved if the CONSORT statement is followed as prescribed.
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OBJECTIVES: Network meta-analysis is often performed with aggregate level data
(AD). A challenge with meta-regression models using AD is that the association
between a patient level covariate and relative treatment effects of the compared
interventions at the study level may not reflect the individual level effect-modifi-
cation. In this paper, non-linear network meta-analysis models for combining in-
dividual patient data (IPD) and AD are presented to reduce bias and uncertainty of
treatment effects in the presence of heterogeneity due to patient characteristics.
METHODS: The first method uses the same model form for IPD and AD. With the
second method, the model for AD is obtained by integrating an underlying IPD
model over the joint within-study distribution of covariates. With a simple simu-
lation study the twomodeling approaches are compared. RESULTS:Having IPD for
a subset of studies improves estimation of treatment effects with network meta-
analysis in the presence of patient level heterogeneity and inconsistency. Of the
two proposed non-linear models for combining IPD and AD, the second approach
seems less affected by bias. Additional studies, however, are needed to assess the
value of both methods. CONCLUSIONS: Overall, for network meta-analysis it is
recommended to use IPD when available, rather than treating all studies as AD.
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OBJECTIVES: To develop an instrument that identifies patient groups likely to have
differing responses to treatment, we tested candidate measures thought to dis-
criminate differences among patients in 4 disease cohorts: type 2 diabetes (T2D),
knee osteoarthritis (OA), ischemic heart disease (IHD) and heart failure (HF).
METHODS: Eligible patients identified from claims data were sent a survey includ-
ing 17 scales hypothesized to comprise 4 domains (health profile, personality, be-
havior, life context). Proxies for treatment response were patient-reported global
impression of disease severity (PGIS), global impression of improvement (PGII), and
administrative claims health care utilization (HCU). Variability (SD) and internal
consistency (Cronbach’s alpha) of the scales were examined, as was discriminant
validity against strata of PGIS, PGII and HCU. Conceptual overlap, correlations
among scales, and factor loading within and across domains were examined.
Scales with desirable properties were included in the final instrument. Discrimi-
nant validity of proposed domains was analyzed by ANOVA adjusted for age and
gender. Multiple regression models were used to assess the associations between
the proposed domains and outcomes. RESULTS: A total of 723 T2D patients, 682
knee OA patients, 632 IHD patients, and 588 HF patients completed the survey. The
initial instrument was refined to 7 scales across 3 domains. The health profile
domain significantly discriminated 100% of the strata across disease cohorts (each
P0.001). Personality and behavior domains also discriminated strata well (75%
and 50%, respectively). Alone, the health profile significantly discriminated strata
across disease cohorts in multivariate analyses (each P 0.001). In models includ-
ing all 3 domains, the health profile remained the most important contributor.
CONCLUSIONS: The final ENSEMBLE MDS instrument discriminated among pa-
tients with varied diseases; the health profile provided much of the ability to dis-
criminate. Further research is needed to assess the instrument’s potential to pre-
dict health state changes due to trial interventions.
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OBJECTIVES: A better understanding of a patient’s genetic make-up through phar-
macogenomic testing can help achieve improved and more predictable patient
outcomes, often at equal or lower total treatment cost. Stakeholders including
physicians, payers andpatients alike can benefit from real-world data that identify,
a priori, the sub-groups of patients for whom treatments are likely to be more
cost-effective.METHODS: Retrospective and prospective case study designswithin
which pharmacogenomic testing has been integrated are presented. Design pa-
rameters are described and opportunities and challenges alongside strategies for
resolution are delineated. RESULTS: As the genetic make-up of a patient does not
change, pharmacogenomic testing can be done at any point in time andpairedwith
historical and/or newly collected patient level data. Retrospective studies are
highly efficient as they do not require costly longitudinal follow-up, whereas pro-
spective studies including registries offer the opportunity to augment pharmacog-
enomic and other study data with patient and physician reported outcomes not
otherwise available in the medical chart. Main challenges associated with either
approach include optimizing the patient informed consent process, streamlining
the logistics associated with pharmacogenomic testing and storage in the usual
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